Clinical Trial Update: MRKAd5 HIV-1 Gag Vaccine (V520) in Subjects With Chronic Hepatitis C (V520-022) (COMPLETED) [Phase 1]

View source ↗

Summary

Phase 1 trial of MRKAd5 HIV-1 Gag Vaccine (V520) in adults with chronic hepatitis C has completed and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• MRKAd5 HIV-1 Gag Vaccine (V520)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C | Phase 1 | Status: COMPLETED | Results posted: 2011-07-07